Læknablaðið - sep. 2020, Blaðsíða 16

402 L ÆK N A BL AÐIÐ 2020/106
R A N N S Ó K N
1. WHO. gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf - september
2019.
2. NORDCAN. Staðreyndir um krabbamein. Ísland - Brjóst. dep.iarc.fr/NORDCAN/ICE/
StatsFact.asp?cancer=200&country=352. - september 2019.
3. NORDCAN. Staðreyndir um krabbamein. Svíþjóð - Brjóst. dep.iarc.fr/NORDCAN/ICE/
StatsFact.asp?cancer=200&country=752. - september 2019.
4. Seely JM, Alhassan T. Screening for breast cancer in 2018 - what should we be doing today?
Curr Oncol 2018; 25 (Suppl 1): S115-S124.
5. Samverkan, R.c.i. Gällande vårdprogram bröstcancer. 2019 - september 2019.
6. Krabbameinsfélagið. Brjóstakrabbamein. Helstu einkenni, orsakir, greining, algengi og
lífshorfur. krabb.is/fraedsla-forvarnir/krabbamein-a-o/brjostakrabbamein/ -
7. Sigurdsson K, Olafsdóttir EJ. Population-based service mammography screening: the
Icelandic experience. Breast cancer 2013; 5: 17-25.
8. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2019; 30: 1194-220.
9. Giuliano AE, Connolly JL, Edge SE, et al. Breast Cancer—Major changes in the American
Joint Committee on Cancer eighth edition cancer staging manual. CA A Cancer J Clinic
2017; 67: 290-303.
10. Velferðarráðuneytið. Markmið og aðgerðir í tillögu að íslenskri krabbameinsáætl-
un til ársins 2020. stjornarradid.is/lisalib/getfile.aspx?itemid=b93f90f1-631d-11e-
7-9416-005056bc4d74 - maí 2018.
11. Velferðarráðuneytið. Tillaga að íslenskri krabbameinsáætlun til ársins 2020. stjornarradid.
is/lisalib/getfile.aspx?itemid=c43ad131-631d-11e7-9416-005056bc4d74 - september 2016.
12. Cancercentrum, R. ANMÄLAN. Nationellt kvalitetsregister för bröstcancer 2018.
cancercentrum.se/globalassets/cancerdiagnoser/brost/kvalitetsregister/brostanm_
version2.0.0_2017-10-31.pdf - september 2018.
13. Cancercentrum, R. OPERATION. Nationellt kvalitetsregister för bröstcancer 2018; - sept-
ember 2018.
14. Cancercentrum, R. GIVEN PRE- ELLER POSTOPERATIV ADJUVANT ONKOLOGISK
BEHANDLING. Nationellt kvalitetsregister för bröstcancer 2018 ; cancercentrum.se/
globalassets/cancerdiagnoser/brost/kvalitetsregister/brostonkologiskbeh_version2.0.0.pdf -
apríl 2018.
15. Cancercentrum, R. POSTOPERATIVA LOKO-REGIONALA RECIDIV /
FJÄRRMETASTASER. Nationellt kvalitetsregister för bröstcancer 2018: cancercentrum.se/
globalassets/cancerdiagnoser/brost/kvalitetsregister/brost_recidiv-fjarrmet_version2.0.0.pdf
- september 2018.
16. Krabbameinsfélagið. Ársskýrsla 2012-2013. krabb.is/media/baeklingar/
Arsskyrsla20122013Krabbameinsfelagid2.pdf - maí 2018.
17. Krabbameinsfélagið. Ársskýrsla 2016-2017. krabb.is/media/baeklingar/2018-03-19-Arsskyr-
sla-2016-2017-Krabbameinsfelagid.pdf - maí 2018.
18. Törnberg S, Lidbrink E, Henriksson R. Avgiftsfri mammografi får fler att komma till und-
ersökning. Läkartidningen 2014; 111: 15.
19. Kesson EM, Allardice GM, George WD, et al. Effects of multidisciplinary team working
on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722
women. BMJ 2012; 344: e2718-e2718.
20. Fisher B, Anderson S, Bryant J, et al. Twenty-Year Follow-up of a Randomized Trial
Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the
Treatment of Invasive Breast Cancer. N Engl J Med 2002; 347: 1233-41.
21. van Maaren MC, Munck LD, Bock GHD, et al. 10 year survival after breast-conserving
surgery plus radiotherapy compared with mastectomy in early breast cancer in the
Netherlands: a population-based study. Lancet Oncol 2016; 17: 1158-1170.
22. Hofvind S, Holen A, Aas T, et al. Women treated with breast conserving surgery do better
than those with mastectomy independent of detection mode, prognostic and predictive
tumor characteristics. Eur J Surg Oncol 2015; 41: 1417-22.
23. Brownlee Z, Garg R, Listo M, et al. Late complications of radiation therapy for breast
cancer: evolution in techniques and risk over time. Gland Surgery 2018; 7: 371-8.
24. Ágústsson AS. Ductal carcinoma in situ á Íslandi 2008-2014 og samanburður greiningar og
meðferðar við Svíþjóð. http://hdl.handle.net/1946/27585 - september 2017.
Lilja Dögg Gísladóttir1
Helgi Birgisson3
Bjarni A. Agnarsson1,2
Þorvaldur Jónsson2
Laufey Tryggvadóttir1,3
Ásgerður Sverrisdóttir2
Correspondence: Lilja Dögg Gísladóttir, ldg5@hi.is
Key words: Breast cancer, Quality registration,
Diagnosis, Treatment.
E N G L I S H S U M M A R Y
Comparison of diagnosis and treatment of invasive breast cancer between Iceland and Sweden
PURPOSE: As part of the implementation of quality registration in Iceland we used retro-
spective data to compare diagnosis and treatment of invasive breast cancer between
Iceland and Sweden.
MATERIALS AND METHODS: Information on all patients diagnosed with invasive breast
cancer in Iceland 2016-2017 was obtained from the Icelandic Cancer Registry. Hospital
records were used to register variables in an electronic form adapted from the Swedish
quality registration, and compared with data from Sweden for the same period. A chi-squ-
are test was used to compare ratios.
RESULTS: A total of 486 cases of breast cancer were diagnosed in Iceland and 15.325 in
Sweden. A lower proportion of 40-69 year old women were diagnosed within the screening
programme in Iceland (46%) compared to Sweden (60%) (p<0,01). Multidisciplinary tumor
board meetings held before and after surgery were less frequent in Iceland (92% vs. 96%)
compared to Sweden (98% vs. 99%) in 2016 (p<0,01) but no difference was seen in 2017. A
sentinel node surgery was done in 69% of the cases in Iceland compared to 94% in Sweden
(p<0,01). For cancers ≤30mm breast conserving surgery was done in 48% cases in Iceland
but 80% in Sweden (p<0,01). In Iceland 87% of the cases had radiation therapy after breast
conserving surgery but 94% in Sweden (p<0,01). Among mastectomy patients with lymph
node metastases, 49% received radiation therapy in Iceland compared to 83% in Sweden
(p<0,01).
CONCLUSION: Differences were seen in several areas of diagnosis and treatment of
invasive breast cancer between Iceland and Sweden. With quality registration it will be
possible to monitor and set goals for the diagnosis and treatment, with the aim of providing
the best treatment to as many patients as possible.
1Faculty of Medicine, University of Iceland, Reykjavík, Iceland,
2University Hospital of Iceland, Reykjavík, Iceland, 3Icelandic
Cancer Registry, Reykjavík, Iceland.
Heimildir
Barst til blaðsins 22. maí 2020, samþykkt til birtingar 21. ágúst 2020.